Liraglutide for Management of Obesity in People Living With HIV on Dolutegravir-based Antiretroviral Therapy: a Single-arm Acceptability Study in South Africa

Registration

Registration

NCT06438146

Acronym

LIROH

Study type

INTERVENTIONAL

Phase

PHASE4

Masking

NONE

Status

UNKNOWN

Enrollment

40

Start

2024-05-02

Primary completion

2025-05

Lead sponsor

Brigham and Women's Hospital

Conditions

Obesity; HIV Infections

Interventions

DRUG:Liraglutide

Results posted

FALSE

Individual participant data sharing

YES

Secondary identifiers

NIH:K23DK125162

Registered primary outcomes

• Proportion of participants who screen and enroll among those approached [Measured at screening]
• Time to reach study enrollment target [Measured at enrollment]
• Study retention rate at 12 weeks [Measured at Visit 4 at 12 weeks]
• Study retention rate at 24 weeks [Measured at End of Study at 24 weeks]
• Rate of adherence to treatment over 12 weeks [Measured at Visit 4 at 12 weeks]
• Embedded qualitative interviews regarding the acceptability of liraglutide for obesity management [Measured at End of Study at 24 weeks]